Advertisement

Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM)

      Highlights

      • Triple-goal achievement reduces risks for diabetes complications and mortality.
      • Compared to A1c and BP, achieving LDL-C goal is more likely to reduce risks.
      • Multi-faceted diabetes management may improve long-term health outcomes.

      Abstract

      Aims

      This study was designed to compare the risk of long-term health outcomes, including microvascular, macrovascular complications and mortality, across 4 cohorts: triple-goal, dual-goal, single-goal, and no-goal achievers.

      Methods

      A retrospective cohort of 53,120 patients with T2DM were identified (97.51% male, 61.49% whites) from the Veterans Affairs (VA) electronic medical records VISN 16 data warehouse (2004–2010). Propensity score weight (PSW) was used to balance demographic characteristics and complication history at baseline. The PSW adjusted hazard ratios (aHR) from Cox proportional hazard models were used to compare complications and all-cause mortality over an average of 4 years of follow-up.

      Results

      At baseline, 25.43% (13,507) patients achieved triple-goal, while 41.36% (21,972) and 26.37% (14,010) patients achieved dual-goal and single-goal, respectively. During the follow-up period, triple-goal achievement was associated with risk reductions of complications and all-cause mortality when compared to all other groups of achieving dual or single-goal. Across different combinations of dual-goal achievement, the cohort with LDL-C goal achievement had lower risk of complication events and mortality, compared to those that achieved other goals but failed to reach LDL-C goal.

      Conclusions

      Achievement of triple-goal was associated with better health outcomes among veterans with T2DM compared to those that did not, while LDL-C has more weight of influence. Multi-faceted treatment strategies targeting hypertension, hyperglycemia and hyperlipidemia may improve health outcome in veterans with T2DM.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boyle J.P.
        • Thompson T.J.
        • Gregg E.W.
        • Barker L.E.
        • Williamson D.F.
        Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.
        Popul Health Metr. 2010; 8: 29
        • American Diabetes A.
        Economic costs of diabetes in the U.S. in 2012.
        Diabetes Care. 2013; 36: 1033-1046
        • Raman R.
        • Gupta A.
        • Krishna S.
        • Kulothungan V.
        • Sharma T.
        Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27).
        J Diabetes Complicat. 2012; 26: 123-128
        • Candrilli S.D.
        • Meyers J.L.
        • Boye K.
        • Bae J.P.
        Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities.
        J Diabetes Complicat. 2014;
        • Harzallah F.
        • Ncibi N.
        • Alberti H.
        • Ben Brahim A.
        • Smadhi H.
        • Kanoun F.
        • et al.
        Clinical and metabolic characteristics of newly diagnosed diabetes patients: experience of a university hospital in Tunis.
        Diabetes Metab. 2006; 32: 632-635
        • Hermans M.P.
        • Elisaf M.
        • Michel G.
        • Muls E.
        • Nobels F.
        • Vandenberghe H.
        • et al.
        Benchmarking is associated with improved quality of care in type 2 diabetes.
        Diabetes Care. 2013; 36: 3388-3395
        • Nichols G.A.
        • Joshua-Gotlib S.
        • Parasuraman S.
        Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.
        J Gen Intern Med. 2013; 28: 691-697
        • Kong A.P.
        • Yang X.
        • Ko G.T.
        • So W.-Y.
        • Chan W.-B.
        • Ma R.C.
        • et al.
        Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes.
        Diabetes Care. 2007; 30: 953-959
        • Hoerger T.J.
        • Segel J.E.
        • Gregg E.W.
        • Saaddine J.B.
        Is glycemic control improving in U.S. adults?.
        Diabetes Care. 2008; 31: 81-86
        • Shi L.
        • Ye X.
        • Lu M.
        • Wu E.Q.
        • Sharma H.
        • Thomason D.
        • et al.
        Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.
        Diabetes Care. 2013; 36: 3297-3304
        • Gaede P.
        • Vedel P.
        • Larsen N.
        • Jensen G.V.
        • Parving H.H.
        • Pedersen O.
        Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
        N Engl J Med. 2003; 348: 383-393
        • Gaede P.
        • Lund-Andersen H.
        • Parving H.H.
        • Pedersen O.
        Effect of a multifactorial intervention on mortality in type 2 diabetes.
        N Engl J Med. 2008; 358: 580-591
        • Rohlfing C.L.
        • Wiedmeyer H.M.
        • Little R.R.
        • England J.D.
        • Tennill A.
        • Goldstein D.E.
        Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.
        Diabetes Care. 2002; 25: 275-278
        • McCaffrey D.F.
        • Griffin B.A.
        • Almirall D.
        • Slaughter M.E.
        • Ramchand R.
        • Burgette L.F.
        A tutorial on propensity score estimation for multiple treatments using generalized boosted models.
        Stat Med. 2013; 32: 3388-3414
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Turner R.
        • Millns H.
        • Neil H.
        • Stratton I.
        • Manley S.
        • Matthews D.
        • et al.
        Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).
        BMJ. 1998; 316: 823-828
        • Association A.D.
        Standards of medical care in diabetes–2015: summary of revisions.
        Diabetes Care. 2015; 38: S4
        • Group A.S.
        • Ginsberg H.N.
        • Elam M.B.
        • Lovato L.C.
        • Crouse 3rd, J.R.
        • Leiter L.A.
        • et al.
        Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Sabatine M.S.
        • Giugliano R.P.
        • Wiviott S.D.
        • Raal F.J.
        • Blom D.J.
        • Robinson J.
        • et al.
        Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
        N Engl J Med. 2015; 372: 1500-1509
        • American Diabetes A.
        Standards of medical care in diabetes–2014.
        Diabetes Care. 2014; 37 (S14–80)
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • Cushman W.C.
        • Dennison-Himmelfarb C.
        • Handler J.
        • et al.
        2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 311: 507-520
        • Group A.S.
        • Cushman W.C.
        • Evans G.W.
        • Byington R.P.
        • Goff Jr., D.C.
        • Grimm Jr., R.H.
        • et al.
        Effects of intensive blood-pressure control in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1575-1585
        • Patel A.
        • Group A.C.
        • MacMahon S.
        • Chalmers J.
        • Neal B.
        • Woodward M.
        • et al.
        Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
        Lancet. 2007; 370: 829-840
        • Zoungas S.
        • Chalmers J.
        • Neal B.
        • Billot L.
        • Li Q.
        • Hirakawa Y.
        • et al.
        Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
        N Engl J Med. 2014; 371: 1392-1406
        • Group AC
        • Patel A.
        • MacMahon S.
        • Chalmers J.
        • Neal B.
        • Billot L.
        • et al.
        Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
        N Engl J Med. 2008; 358: 2560-2572
        • Action to Control Cardiovascular Risk in Diabetes Study G
        • Gerstein H.C.
        • Miller M.E.
        • Byington R.P.
        • Goff Jr., D.C.
        • Bigger J.T.
        • et al.
        Effects of intensive glucose lowering in type 2 diabetes.
        N Engl J Med. 2008; 358: 2545-2559
        • Camara S.
        • Bouenizabila E.
        • Hermans M.P.
        • Ahn S.A.
        • Rousseau M.F.
        Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes.
        Diabetes Metab Synd: Clin Res Rev. 2014; 8: 145-151